Találati lista | Tudóstér

001-es BibID:	BIBFORM116102
035-os BibID:	(Scopus)85164401622 (WOS)001017815400001
Első szerző:	Banach, Maciej
Cím:	Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab : a subanalysis of the ODYSSEY APPRISE study / Banach Maciej, Lewek Joanna, Pol Kaja, Rabczenko Daniel, Balanescu Serban M., Blaha Vladimir, Ceska Richard, Jankowski Piotr, Surma Stanisaw, Kolovou Genovefa, Liberopoulos Evangelos, Mitu Florin, Mitu Magda, Naji Franjo Husam, Paragh Gyorgy, Popawska Magdalena, Vrablik Michal, Pella Daniel
Dátum:	2023
ISSN:	2297-055X
Megjegyzések:	BackgroundDespite better accessibility of the effective lipid-lowering therapies, only about 20% of patients at very high cardiovascular risk achieve the low-density lipoprotein cholesterol (LDL-C) goals. There is a large disparity between European countries with worse results observed for the Central and Eastern Europe (CEE) patients. One of the main reasons for this ineffectiveness is therapeutic inertia related to the limited access to appropriate therapy and suitable dosage intensity. Thus, we aimed to compare the differences in physicians' therapeutic decisions on alirocumab dose selection, and factors affecting these in CEE countries vs. other countries included in the ODYSSEY APPRISE study.MethodsODYSSEY APPRISE was a prospective, single-arm, phase 3b open-label (& GE;12 weeks to & LE;30 months) study with alirocumab. Patients received 75 or 150 mg of alirocumab every 2 weeks, with dose adjustment during the study based on physician's judgment. The CEE group in the study included Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia, which we compared with the other nine European countries (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Spain, and Switzerland) plus Canada.ResultsA total of 921 patients on alirocumab were involved [modified intention-to-treat (mITT) analysis], including 114 (12.4%) subjects from CEE countries. Therapy in CEE vs. other countries was numerically more frequently started with lower alirocumab dose (75 mg) at the first visit (74.6 vs. 68%, p = 0.16). Since week 36, the higher dose was predominantly used in CEE patients (150 mg dose in 51.6% patients), which was maintained by the end of the study. Altogether, alirocumab dose was significantly more often increased by CEE physicians (54.1 vs. 39.9%, p = 0.013). Therefore, more patients achieved LDL-C goal at the end of the study (<55 mg/dl/1.4 mmol/L and 50% reduction of LDL-C: 32.5% vs. 28.8%). The only factor significantly influencing the decision on dose of alirocumab was LDL-C level for both countries' groups (CEE: 199.2 vs. 175.3 mg/dl; p = 0.019; other: 205.9 vs. 171.6 mg/dl; p < 0.001, for 150 and 75 mg of alirocumab, respectively) which was also confirmed in multivariable analysis (OR = 1.10; 95% CI: 1.07-1.13).ConclusionsDespite larger unmet needs and regional disparities in LDL-C targets achievement in CEE countries, more physicians in this region tend to use the higher dose of alirocumab, they are more prone to increase the dose, which is associated with a higher proportion of patients reaching LDL-C goals. The only factor that significantly influences decision whether to increase or decrease the dose of alirocumab is LDL-C level.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Frontiers in Cardiovascular Medicine. - 10 (2023), p. 1-9. -
További szerzők:	Lewek, Joanna Pol, Kaja Rabczenko, Daniel Balanescu, Serban M. Blaha, Vladimir Ceska, Richard Jankowski, Piotr Surma, Stanisaw Kolovou, Genovefa Liberopoulos, Evangelos Mitu, Florin Mitu, Magda Naji, Franjo Husam Paragh György (1953-) (belgyógyász) Popawska, Magdalena Vrablík, Michal Pella, Daniel
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM083295
Első szerző:	Ceska, Richard
Cím:	The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment : results from the ScreenPro FH Project / Richard Ceska, Gustavs Latkovskis, Marat V. Ezhov, Tomas Freiberger, Katarina Lalic, Olena Mitchenko, Gyorgy Paragh, Zaneta Petrulioniene, Belma Pojskic, Katarina Raslova, Aleksandr B. Shek, Branislav Vohnout, Tereza Altschmiedova, Veronika Todorovova
Dátum:	2019
ISSN:	1523-3804 1534-6242
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Current Atherosclerosis Reports. - 21 : 9 (2019), p. 1-12. -
További szerzők:	Latkovskis, Gustavs Ezhov, Marat V. Freiberger, Tomas Lalic, Katarina Mitchenko, Olena Paragh György (1953-) (belgyógyász) Petrulioniene, Zaneta Pojskic, Belma Rašlová, Katarína Shek, Alexander B. Vohnout, Branislav Altschmiedova, Tereza Todorovova, Veronika
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM069810
Első szerző:	Ceska, Richard
Cím:	ScreenPro FH - Screening project for familial hypercholesterolemia in central, Southern and Eastern Europe : basic epidemiology / Češka R., Freiberger T., Susekov A. V., Paragh G., Reiner Z., Tokgözoglu L., Rašlová K., Banach M., Vohnout B., Rynkiewicz A., Goudev A., Dan G. A., Gaita D., Pojskic B., Pecin I., Kayikçioğlu M., Mitchenko O., Ezhov M. V., Latkovskis G., Petrulioniene Z., Fras Z., Tasic N., Mirrakhimov E. M., Murataliev T., Shek A. B., Tuka V., Tselepis A. D., Moubarak E. M., Al Rasadi K.
Dátum:	2017
Megjegyzések:	Introduction: Despite great recent progress, familial hypercholesterolemia (FH) is still underestimated, under-diagnosed and thus undertreated worldwide. We have very little information on exact prevalence of patients with FH in the Central, Eastern and Southern Europe (CESE) region. The aim of the study was to describe the epidemiological situation in the CESE region from data available. Methods: All local leaders of the ScreenPro FH project were asked to provide local data on (a) expert guess of FH prevalence (b) the medical facilities focused on FH already in place (c) ScreenPro FH - projekt v oblasti screeningu zam?e?ren℗y na familiární hypercholesterolemii ve st?rední, ji?zní a v℗ychodní Evrop?e: základní epidemiologie diagnosis - epidemiology - familial hypercholesterolemia - screening the diagnostic criteria used (d) the number of patients already evidenced in local database and (e) the availability of therapeutic options (especially plasma apheresis). Results: With the guess prevalence of FH around 1:500, we estimate the overall population of 588 363 FH heterozygotes in the CESE region. Only 14 108 persons (2.4 %) were depicted in local databases; but the depiction rate varied between 0.1 % and 31.6 %. Only four out of 17 participating countries reported the the LDL apheresis availability. Conclusion: Our data point to the large population of heterozygous FH patients in the CESE region but low diagnostic rate. However structures through the ScreenPro FH project are being created and we can hope that the results will appear soon.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Internal medicine Endocrinology Diabetology
Megjelenés:	Vnitrni Lekarstvi 63 : 1 (2017), p. 25-30. -
További szerzők:	Freiberger, Tomas Susekov, Andrey Paragh György (1953-) (belgyógyász) Reiner, Željko Tokgözoğlu, Lale Rašlová, Katarína Banach, Maciej Vohnout, Branislav Rynkiewicz, Andrzej Goudev, Assen Dan, George Andrei Gaita, Dan Pojskic, Belma Pećin, Ivan Kayikcioglu, Meral Mitchenko, Olena Ezhov, Marat V. Latkovskis, Gustavs Petrulioniene, Zaneta Fras, Zlatko Tasic, Nebojsa Mirrakhimov, Erkin Murataliev, Tolkun Shek, Alexander B. Tuka, Vladimír Tselepis, Alexandros D. Moubarak, Elie M. Al Rasadi, Khalid
Internet cím:	Szerző által megadott URL Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM069504
Első szerző:	The EAS Familial Hypercholesterolaemia Studies Collaboration
Cím:	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes : rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration / The EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz Antonio J., Akram Asif, Kondapally Seshasai Sreenivasa Rao, Cole Della, Watts Gerald F., Hovingh G. Kees, Kastelein John J. P., Mata Pedro, Raal Frederick J., Santos Raul D., Soran Handrean, Freiberger Tomas, Abifadel Marianne, Aguilar-Salinas Carlos A., Alnouri Fahad, Alonso Rodrigo, Al-Rasadi Khalid, Banach Maciej, Bogsrud Martin P., Bourbon Mafalda, Bruckert Eric, Car Josip, Ceska Richard, Corral Pablo, Descamps Olivier, Dieplinger Hans, Do Can T., Durst Ronen, Ezhov Marat V., Fras Zlatko, Gaita Dan, Gaspar Isabel M., Genest Jaques, Harada-Shiba Mariko, Jiang Lixin, Kayikcioglu Meral, Lam Carolyn S. P., Latkovskis Gustavs, Laufs Ulrich, Liberopoulos Evangelos, Lin Jie, Lin Nan, Maher Vincent, Majano Nelson, Marais A. David, März Winfried, Mirrakhimov Erkin, Miserez André R., Mitchenko Olena, Nawawi Hapizah, Nilsson Lennart, Nordestgaard Børge G., Paragh György, Petrulioniene Zaneta, Pojskic Belma, Reiner Ẑeljko, Sahebkar Amirhossein, Santos Lourdes E., Schunkert Heribert, Shehab Abdullah, Slimane M. Naceur, Stoll Mario, Su Ta-Chen, Susekov Andrey, Tilney Myra, Tomlinson Brian, Tselepis Alexandros D., Vohnout Branislav, Widén Elisabeth, Yamashita Shizuya, Catapano Alberico L., Ray Kausik K.
Dátum:	2016
ISSN:	1567-5688
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Familial hypercholesterolaemia LDL-Cholesterol Cardiovascular disease Registry Study design Familial Hypercholesterolaemia Studies Collaboration
Megjelenés:	Atherosclerosis Supplements. - 22 (2016), p. 1-32. -
További szerzők:	Vallejo-Vaz, Antonio J. Akram, Asif Kondapally Seshasai, S. R. Cole, Della Watts, Gerald F. Hovingh, G. Kees Kastelein, John J. P. Mata, Pedro Raal, Frederick J. Santos, Raul D. Soran, Handrean Freiberger, Tomas Abifadel, Marianne Aguilar-Salinas, Carlos A. Alnouri, Fahad Alonso, Rodrigo Al-Rasadi, Khalid Banach, Maciej Bogsrud, Martin P. Bourbon, Mafalda Bruckert, Eric Car, Josip Ceska, Richard Corral, Pablo Descamps, Olivier Dieplinger, Hans Do, Can T. Durst, Ronen Ezhov, Marat V. Fras, Zlatko Gaita, Dan Gaspar, Isabel M. Genest, Jaques Harada-Shiba, Mariko Jiang, Lixin Kayikcioglu, Meral Lam, Carolyn S. P. Latkovskis, Gustavs Laufs, Ulrich Liberopoulos, Evangelos Lin, Jie Lin, Nan Maher, Vincent Majano, Nelson Marais, A. David März, Winfried Mirrakhimov, Erkin Miserez, André R. Mitchenko, Olena Nawawi, Hapizah Nilsson, Lennart Nordestgaard, Børge G. Paragh György (1953-) (belgyógyász) Petrulioniene, Zaneta Pojskic, Belma Reiner, Željko Sahebkar, Amirhossein Santos, Lourdes E. Schunkert, Heribert Shehab, Abdullah Slimane, M. Naceur Stoll, Mario Su, Ta-Chen Susekov, Andrey Tilney, Myra Tomlinson, Brian Tselepis, Alexandros D. Vohnout, Branislav Widén, Elisabeth Yamashita, Shizuya Catapano, Alberico L. Ray, Kausik K.
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: